Vanessa M Knab
Overview
Explore the profile of Vanessa M Knab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmalzbauer B, Thondanpallil T, Heller G, Schirripa A, Sperl C, Mayer I, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326705
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer...
2.
Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, et al.
Blood
. 2021 Jul;
138(23):2347-2359.
PMID: 34320169
The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B are critical in hematopoiesis and leukemia. They are widely believed to have redundant functions, but we describe...
3.
Tripolt S, Neubauer H, Knab V, Elmer D, Aberger F, Moriggl R, et al.
Neoplasia
. 2021 Jan;
23(2):270-279.
PMID: 33465556
The opioid crisis of pain medication bears risks from addiction to cancer progression, but little experimental evidence exists. Expression of δ-opioid receptors (DORs) correlates with poor prognosis for breast cancer...
4.
Prinz D, Klein K, List J, Knab V, Menzl I, Leidenfrost N, et al.
Eur J Immunol
. 2020 Feb;
50(6):880-890.
PMID: 32052406
NK cells are innate lymphocytes responsible for lysis of pathogen-infected and transformed cells. One of the major activating receptors required for target cell recognition is the NK group 2D (NKG2D)...
5.
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, et al.
Nat Commun
. 2019 Oct;
10(1):4741.
PMID: 31628323
Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in B-ALL. Loss of CDK8 in leukemia mouse...
6.
Schoos A, Gabriel C, Knab V, Fux D
J Pharmacol Exp Ther
. 2019 Jul;
370(3):480-489.
PMID: 31300611
Opioids promote tumor angiogenesis in mammary malignancies, but the underlying signaling mechanism is largely unknown. The current study investigated the hypothesis that stimulation of -opioid receptors (DOR) in breast cancer...
7.
Schoos A, Knab V, Gabriel C, Tripolt S, Wagner D, Bauder B, et al.
Vet Comp Oncol
. 2019 Jun;
17(4):507-521.
PMID: 31207004
Therapy of canine mammary tumours (CMTs) with classical antitumour drugs is problematic, so better therapeutic options are needed. Palbociclib (PD-0332991) is an innovative and effective anticancer drug for the treatment...
8.
Knab V, Corbin B, Andrukhova O, Hum J, Ni P, Rabadi S, et al.
Endocrinology
. 2017 Mar;
158(5):1130-1139.
PMID: 28324013
The acute effects of parathyroid hormone (PTH) on fibroblast growth factor 23 (FGF23) in vivo are not well understood. After a single subcutaneous PTH (1-34) injection (50 nmol/kg) in mice,...